NFKB1 and cancer: Experiments have also demonstrated that there is a positive feedback relationship between NF-κB signaling and SCD1, so we can suppress the expression of SCD1 by inhibiting the NF-κB signaling pathway to enhance cancer therapy (Li J. et al., 2017; Mukherjee et al., 2017).